AOD-9604: Fat Loss & Metabolic Research Peptide Overview
Fact Checked By
Dr. Alistair J. Vance, PhDSenior Research Fellow, Peptide Synthesis & Metabolic Pathways · PhD Biochemistry
⚠ DISCLAIMER: All products sold by PeptidesUK Healthcare are strictly for laboratory and scientific research purposes only. They are not for human consumption, therapeutic use, or any other application outside of controlled laboratory settings. Researchers must comply with all applicable local, national, and institutional regulations.
AOD-9604 is a synthetic 16-amino acid peptide fragment corresponding to the C-terminal region (amino acids 177–191) of human growth hormone (hGH). Unlike full-length growth hormone, AOD-9604 has been specifically investigated in preclinical and early clinical models for its selective effects on fat metabolism and lipolysis, without the broader anabolic, insulin-resistant, or growth-promoting effects associated with intact hGH.
What is AOD-9604?
AOD-9604 was developed as a potential research tool for studying obesity and metabolic regulation. It retains the lipolytic (fat-breaking) domain of hGH while excluding the regions responsible for IGF-1 stimulation and other systemic effects. This makes it a unique compound for researchers interested in isolating fat metabolism pathways.
In laboratory settings, AOD-9604 is studied for its ability to stimulate lipolysis in adipose tissue and inhibit lipogenesis (fat cell formation), offering a targeted approach to metabolic research.
Mechanism of Action in Research Models
The primary mechanism of AOD-9604 involves activation of the β3-adrenergic receptor pathway in adipocytes, leading to increased fat breakdown and oxidation. Unlike full hGH, it does not appear to significantly elevate IGF-1 levels or cause insulin resistance in the models studied.
Key effects observed in preclinical research include:
- Increased lipolysis in adipose tissue
- Reduced fat accumulation in obese animal models
- Improved lipid profiles without significant metabolic disruption
- No significant impact on blood glucose or insulin sensitivity
These properties make AOD-9604 a valuable tool for dissecting the specific fat-metabolising domain of growth hormone from its broader anabolic and growth-stimulating functions.
Key Research Findings
Heffernan et al. (2001) published foundational preclinical findings in Obesity Research demonstrating that AOD-9604 administration in obese mice produced significant reductions in body fat mass and improvements in metabolic parameters, without the adverse effects typically associated with full-length hGH.
Ng et al. (2000) characterised the metabolic activity of the synthetic lipolytic domain in Hormone Research, providing mechanistic data on how the C-terminal fragment of hGH selectively targets fat oxidation pathways while avoiding IGF-1 stimulation.
Isidro & Casanueva (2005) reviewed AOD-9604's investigational profile in Expert Opinion on Investigational Drugs, summarising early clinical exploration of the compound's safety and tolerability in obesity research contexts.
Researchers continue to use AOD-9604 to better understand selective lipolysis and its potential applications in metabolic syndrome models, adipose tissue biology, and the GH-lipid axis.
Comparison: AOD-9604 vs Full-Length hGH in Research
| Property | AOD-9604 | Full-Length hGH |
|---|---|---|
| IGF-1 Stimulation | Minimal / absent | Significant |
| Lipolytic Activity | Selective and targeted | Present but non-selective |
| Insulin Resistance Risk | Low in studied models | Elevated at higher doses |
| Anabolic Effects | Not observed | Pronounced |
| Research Use | Selective fat metabolism studies | Broad GH axis research |
Quality Standards for Metabolic Research
For reproducible results in fat metabolism studies, peptide purity and batch consistency are critical. Even small impurities can affect receptor binding and lipolytic activity, introducing variables that compromise experimental validity.
Researchers should always verify:
- HPLC purity ≥99% — ensures receptor-grade material
- Mass spectrometry confirmation of correct molecular weight
- Independent third-party laboratory testing — not in-house only
- Full batch-specific Certificates of Analysis — downloadable and traceable
At PeptidesUK Healthcare, every batch of AOD-9604 undergoes rigorous independent testing with complete COAs available for immediate download.
Conclusion and Best Practices
AOD-9604 represents a specialised research peptide for investigating selective fat metabolism and lipolysis pathways. Its ability to target fat breakdown while avoiding many of the broader effects of full growth hormone makes it a unique and valuable tool in metabolic research.
When designing experiments with AOD-9604, researchers should select high-purity, independently verified material and maintain detailed records of lot numbers and handling procedures. Proper reconstitution and storage are critical to preserving biological activity throughout the study.
For detailed guidance on reconstitution, storage, and laboratory handling of metabolic peptides, refer to our Education Centre guide on Reconstitution and Handling of Peptides.
References
-
Heffernan M, et al. (2001). The effects of AOD-9604 on body weight and fat mass in obese mice. Obesity Research. PubMed
-
Ng FM, et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Hormone Research. PubMed
-
Isidro ML & Casanueva FF. (2005). AOD-9604: a new drug for obesity treatment? Expert Opinion on Investigational Drugs. PubMed
© PeptidesUK Healthcare — Elara Healthcare Limited. All products for laboratory research use only.
Dr. A. Richardson
Chief Scientific Officer, BSc (Hons) Biochemistry, PhD Peptide Chemistry
Dr. Richardson holds a PhD in Peptide Chemistry from the University of Edinburgh and has over 15 years of experience in peptide synthesis and quality assurance research.
View credentialsThis article is for informational purposes only and does not constitute medical advice. All referenced products are for laboratory research use only.
